CellMax Life to Present Expanded Test Results For Colorectal Cancer Prevention

Share Article

Findings reveal ability of the FirstSightCRC TM blood test to distinguish healthy people from those with the earliest signs of disease more accurately than any other currently available non-invasive test

News Image
These results are very exciting, as for the first time patients who are reluctant to undergo a colonoscopy may have a highly sensitive non-invasive testing option for pre-cancer.

CellMax Life, a diagnostics company with a proprietary technology to detect precancer and cancer cells in blood, will present new findings at the ASCO Gastrointestinal Cancer Symposium in San Francisco this month, revealing significant advancement in the fight against colorectal cancer. The results from this study show CellMax Life’s blood test, based on its proprietary CMxTM platform, can detect pre-cancers (adenomas) with close to 90 percent accuracy (Area Under the ROC Curve).

Results of the study show that based on enumeration of pre-cancer cells, it is possible to accurately differentiate between healthy patients and those with pre-cancer. Further, an increase in cell count was significantly correlated with an increase in disease severity.

“Colorectal cancer is the second deadliest cancer in the U.S., with 150,000 new cases and $14 billon spent on treatment annually,” said Atul Sharan, Co- Founder and CEO of CellMax Life. “We’re working to change that. Colorectal cancer is preventable when adenomas are detected and removed. In fact, adenoma removal reduces mortality rates from colorectal cancer by 53 percent. CellMax Life’s FirstSightCRC test will increase compliance with colorectal cancer screenings and increase detection rates at the adenoma stage, saving lives.”

The FirstSightCRC TM test detects pre-cancer and cancer cells in blood. The test utilizes a patented technology comprising a micro-fluidic chip with proprietary nano (non-sticky) layer for cell capture, high-affinity antibodies, and a special air-foam release technology to gently release the captured cells enabling high intact cell preservation, and thereby high detection rates of pre-cancer.

The IRB-approved study included 737 adults, 50 years of age or older - a population recommended routine screening by most U.S. guidelines. Of those, 301 were found to be healthy, 111 pre-cancerous (had adenoma) and 325 were confirmed to have cancer. Diseased patients were confirmed by colonoscopy or tumor biopsy. The test results presented a high accuracy for detecting colorectal cancer, with a close to 90 percent accuracy for pre-cancer and 95 percent accuracy for cancer. This was an expanded study; previous test results were presented at ASCO’s Gastrointestinal Symposium in 2018.

“Colon cancer screening is essential to detect and remove pre-cancer polyps,” said Dr Shai Friedland, Chief of Gastroenterology at the Stanford Veterans Administration and lead PI for the ongoing Zenith study to seek FDA-approval for the FirstSightCRC test. “These results are very exciting, as for the first time my patients who are reluctant to undergo a colonoscopy may have a highly sensitive non-invasive testing option for pre-cancer.”

Colorectal cancer incidence is rising among younger adults. New guidelines from the American Cancer Society recommend screening for colorectal cancer starting at age 45, down from 50 years. This means that 20 million from the age of 45-50 are newly eligible for testing. But a shocking 33 million of the eligible 100 million in the 50+ age group have never been tested.

Until now, colonoscopy has been the only screening method with the sensitivity to accurately detect adenomas. Unfortunately, due to its invasive nature only 38 percent of Americans seek this method of screening. Non-invasive options exist that are either stool or blood based; however, these tests miss a majority of pre-cancers, eliminating their preventive role per gastroenterology guidelines.

CellMax Life is poised to change that with the release of these new findings on the effectiveness of its FirstSightCRC test, a first of its kind non-invasive blood test that detects adenomas with the highest accuracy.

About CellMax Life
CellMax Life is a diagnostics company focused on cancer screening with a proprietary technology for detecting precancer and cancer cells in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has a CLIA certified and CAP accredited laboratory at this location. For more information, visit https://cellmaxlife.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jackie Copp
Visit website